Clearside Biomedical Inc. (CLSD) announced Monday morning that its Phase 3 study of suprachoroidal CLS-TA, in patients with macular edema associated with non-infectious uveitis, met its primary endpoint and all of its key secondary endpoints.
from RTT - Before the Bell http://ift.tt/2oM74mZ
via IFTTT
No comments:
Post a Comment